AGEN News & Events

Agenus announced the publication of clinical results from the ovarian cancer cohort of its Phase 1b C-800-01 trial evaluating botensilimab plus balstilimab in The Journal for ImmunoTherapy of Cancer. In this heavily pretreated population, BOT+BAL demonstrated clinically meaningful activity and durable benefit in women with treatment-refractory ovarian cancer, a population with few remaining options. The combination achieved a 23% overall response rate and 31% clinical benefit rate, including durable responses with a median duration of 9.7 months. Median overall survival reached 14.8 months, with an estimated of 75% of patients alive at 12 months. These findings build on results from the broader C-800-01 dataset presented at ESMO 2025, where BOT+BAL showed activity across multiple refractory solid tumors. Collectively, these data reinforce the potential of BOT+BAL to generate meaningful immune responses in cancers historically considered unresponsive to immunotherapy.

Agenus announced the appointment of Jose Iglesias as chief medical affairs officer, effective November 10. Iglesias will lead global medical affairs for botensilimab and balstilimab as the combination advances through Phase 3 evaluation and becomes available in selected countries through early-access mechanisms, including France's Autorisation d'Acces Compassionnel program.

Reports Q3 revenue $30.2M, consensus $80.39M. The company said, "Highlights include government-funded, reimbursed compassionate access in France for botensilimab plus balstilimab, new survival data presented at ESMO and ESMO-GI across more than 400 patients spanning more than five refractory cancers, and initiation of the global Phase 3 BATTMAN trial."